Impact of HER2, EGFR, IGF-1R, and VEGFR expressions on the outcome of chemotherapy for advanced gastric cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 8, 2010, Pages 1489-1496

  Matsubara, Junichi ^a   Hirashima, Yoshinori ^b   Yamada, Yasuhide ^c  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b OITA UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Epidermal growth factor receptor (EGFR); Gastric cancer; HER2; Insulin like growth factor receptor (IGF 1R); Vascular endothelial growth factor receptor (VEGFR)

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CYTOPLASM; GASTRECTOMY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIMARY TUMOR; PROTEIN EXPRESSION; STOMACH CANCER; STROMA CELL; TREATMENT OUTCOME; TUMOR CELL;

EID: 79961112844     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Boku N, Yamamoto S, Fukuda H, et al: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer a randomised phase 3 study. Lancet Oncol 10(11): 1063-1069, 2009.
2. Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3): 215-221, 2008.
3. Van Cutsem E, Kang Y, Chung H, et al: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27: 18s (abstr LBA4509), 2009.
4. Pinto C, Di Fabio F, Barone C, et al: Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 101(8): 1261-1268, 2009.
5. Shah MA, Ramanathan RK, Ilson DH, et al: Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24(33): 5201-5206, 2006.
6. Karp DD, Paz-Ares LG, Novello S, et al: Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27 (15): 2516-2522, 2009.
7. Matsubara J, Yamada Y, Hirashima Y, et al: Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res 14(10): 3022-3029, 2008.
8. Hirashima Y, Yamada Y, Matsubara J, et al: Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer. Cancer Sci 100(2): 310-315, 2009.
9. WHO handbook for reporting results of cancer treatment Geneva (Switzerland): World Health Organization Offset Publication. No. 48, 1979.
10. Hayward JL, Rubens RD, Carbone PP, et al: Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. Eur J Cancer 14(11): 1291-1292, 1978. (Pubitemid 9051717)
11. Onn A, Correa AM, Gilcrease M, et al: Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 10(1 Pt 1): 136-143, 2004. (Pubitemid 38114172)
12. Cunningham MP, Essapen S, Thomas H, et al: Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol 28(2): 329-335, 2006.
13. Yokoyama Y, Charnock-Jones DS, Licence D, et al: Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res 9(4): 1361-1369, 2003.
14. Ellis LM and Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8(8): 579-591, 2008.
15. Iwasaki J and Nihira S: Anti-angiogenic therapy against gastrointestinal tract cancers. Jpn J Clin Oncol 39(9): 543-551, 2009.
16. Fischer C, Mazzone M, Jonckx B, et al: FLT1 and its ligands VEGFB and PIGF: drug targets for anti-angiogenic therapy ? Nat Rev Cancer 8(12): 942-956, 2008.
17. Tammela T, Zarkada G, Wallgard E, et al: Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454(7204): 656-660, 2008.
18. Chakravarti A, Loeffler JS and Dyson NJ: Insulin-like growth factor receptor I mediates resistance to antiepidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62 (1): 200-207, 2002. (Pubitemid 34074005)
19. Lu Y, Zi X, Zhao Y, et al: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93(24): 1852-1857, 2001.